2018 No. 960
Prisons, England And Wales
Young Offender Institutions, England And Wales

The Prison and Young Offender Institution (Amendment) (No. 2) Rules 2018

Made
Laid before Parliament
Coming into force
The Secretary of State makes the following Rules in exercise of the powers conferred by section 47(1) and (3A) of the Prison Act 19521.

Citation and commencement1.

These Rules may be cited as the Prison and Young Offender Institution (Amendment) (No. 2) Rules 2018 and come into force on 19th October 2018.

Amendment of the Prison Rules 19992.

(1)

The Prison Rules 19992 are amended as follows.

(2)

In rule 2(1) (interpretation)3, for the definition of “specified drug”, substitute—

““specified drug” means any product or substance containing one or more of the chemical compounds listed in Schedule 2 to these Rules;”.”

(3)

In rule 85(1) (revocations and savings), for “the Schedule,” substitute “Schedule 1”.

(4)

In the Schedule (revocations), for the heading “Schedule” substitute “Schedule 1”.

(5)

After Schedule 1 as renamed, insert Schedule 2 as set out in the Schedule to these Rules.

Amendment of the Young Offender Institution Rules 20003.

(1)

The Young Offender Institution Rules 20004 are amended as follows.

(2)

In each of the following, for “the Schedule” substitute “Schedule 1”–

(a)

Rule 1(b) (citation and commencement), and

(b)

Rule 89(1) (revocations and savings).

(3)

In rule 2(1) (interpretation)5, for the definition of “specified drug”, substitute—

““specified drug” means any product or substance containing one or more of the chemical compounds listed in Schedule 2 to these Rules;”.”

(4)

In the Schedule (revocations), for the heading “Schedule” substitute “Schedule 1”.

(5)

After Schedule 1 as renamed, insert Schedule 2 as set out in the Schedule to these Rules.

Lucy Frazer
Parliamentary Under-Secretary of State
Ministry of Justice

SCHEDULE

Rules 2(5) and 3(5)

“SCHEDULE 2Definition of specified drug

Rule 2(1)

  1. (a)

    AB-PINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide);

  2. (b)

    5F-AB-PINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-Fluoropentyl)-1H-indazole-3-carboxamide);

  3. (c)

    AB-FUBINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide);

  4. (d)

    APICA (1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide);

  5. (e)

    5F-APICA (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide);

  6. (f)

    APINACA (1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide);

  7. (g)

    5F-APINACA (1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide);

  8. (h)

    5F-PB22 (1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid);

  9. (i)

    MDMB-CHMICA (methyl 2-{[1-(cyclohexylmethyl)-1H-indol-3-yl]formamido}-3,3-dimethylbutanoate);

  10. (j)

    PB-22 (Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate);

  11. (k)

    5F-MDMB-PINACA (Methyl-[2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate]);

  12. (l)

    AB-CHMINACA (N-[-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

  13. (m)

    5F-AMB (Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}amino)-3-methylbutanoate);

  14. (n)

    AMB-FUBINACA (Methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-methylbutanoate);

  15. (o)

    Etizolam (4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine);

  16. (p)

    ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

  17. (q)

    MDMB-CHMCZCA (Methyl 2-(9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate);

  18. (r)

    EMB-FUBINACA (Ethyl 2-[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3-methyl-butanoate);

  19. (s)

    5F-Cumyl-PINACA (5-(5-fluoropentyl)-2-(1-methyl-1-phenylethyl)-pyrido[4,3-b]indol-1-one);

  20. (t)

    THJ-018 (1-Naphthalenyl (1-pentyl-1H-indazol-3-yl)-methanone);

  21. (u)

    Cumyl-PEGACLONE (2-(1-Methyl-1-phenyl-ethyl)-5-pentyl-pyrido[4,3-b]indol-1-one);

  22. (v)

    Cumyl-PICA (1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide);

  23. (w)

    Cumyl-THPINACA (N-(2-phenylpropan-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1-H-indazole-3-carboxamide;

  24. (x)

    Norfludiazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one);

  25. (y)

    Nifoxipam 5-(2-fluorophenyl)-3-hydroxy-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one;

  26. (z)

    Gabapentin - 1-(amino methyl)-cyclohexane acetic acid;

  27. (z1)

    Pregabalin - (S)-3-(aminomethyl)-5-methylhexanoic acid;

  28. (z2)

    Mirtazapine - 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine;

  29. (z3)

    Amitriptyline - 3-(5,6-dihydrodibenzo[2,1-b:1’,2’-e][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine;

  30. (z4)

    Quetiapine - (2-(2-(4-dibenzo [b,f][1,4]thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol);

  31. (z5)

    Sertraline - (1S, 4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;

  32. (z6)

    Citalopram - 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;

  33. (z7)

    Venlafaxine - 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;

  34. (z8)

    Carbamazepine – benzo[b][1]benzazepine-11-carboxamide;

  35. (z9)

    Cetirizine - 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;

  36. (z10)

    Chlorpromazine - 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine;

  37. (z11)

    Fluoxetine N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;

  38. (z12)

    Haloperidol - 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;

  39. (z13)

    Lamotrigine - 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine;

  40. (z14)

    Naproxen - (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid;

  41. (z15)

    Nefopam - 5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine;

  42. (z16)

    Olanzapine - 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine;

  43. (z17)

    Paroxetine - (3S,4R)-3-[(1,3-benzodioxol-5-yloxymethyl]-4-(4-fluorophenyl)-piperidine;

  44. (z18)

    Promethazine - N,N,α-Trimethyl-10H-phenothiazine-10-ethanamine;

  45. (z19)

    Sildenafil - 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;

  46. (z20)

    Trazodone - 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one;

  47. (z21)

    Varenicline -7,8,9,10-tetrahydro-6,10-methanol-6H-ptyrazine[2,3-h][3]benzapine;

  48. (z22)

    Zopiclone - 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate;

  49. (z23)

    Zuclopenthixol - 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanoldihydrochloride.”

EXPLANATORY NOTE
(This note is not part of the Rules)

These Rules amend the Prison Rules 1999 (S.I. 1999/728) (“the 1999 Rules”) and the Young Offender Institution Rules 2000 (S.I. 2000/3371) (“the 2000 Rules”). These Rules substitute the definition of “specified drug” in rule 2(1) of the 1999 Rules and rule 2(1) of the 2000 Rules with a revised definition in rule 2(1) and a new Schedule 2. Products or substances that fall within the revised definitions are “specified drugs” for the purposes of section 16A (testing prisoners for drugs) of the Prison Act 1952 (c. 52) (“the Act.”). The effect of section 16A of the Act is that a prison officer can require a prisoner or an inmate to provide a sample for the purpose of ascertaining whether there is a specified drug in the body of the prisoner or inmate. These Rules amend the definition of “specified drug” to include a number of additional chemical compounds. These comprise of a mixture of psychoactive substances, prescription only medicines and pharmacy medicines. The effect of the amendment is that prisoners and inmates can be tested for these additional substances.

A full impact assessment has not been produced for this instrument as no impact on the private, voluntary or public sectors is foreseen.